Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism

Journal of Thrombosis and Thrombolysis(2022)10.1007/s11239-022-02668-8Source: DataRank Database

Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism is a research paper published in Journal of Thrombosis and Thrombolysis (2022). On theSindex it has a DataRank of 0. It has been cited 16 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

16 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 2.31)OA: closedTopics (45)IDs (PubMed, OpenAlex)SDGs (3)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (0/2)

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Courtney Shakowski,Toby C. Trujillo ORCID,Garth Wright ORCID,Scott W. Mueller ORCID,Tyree H. Kiser ORCID

Live enrichment

PubMed:35689140 OpenAlex:https://openalex.org/W4281958946

National Institutes of Health

Grant: UL1TR002535

National Institutes of Health

Grant: 3UL1TR002535-03S1

NIH Prior Approval Process Professional

FWCI

2.31

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

closedLicense: Springer TDM

publisherhttps://link.springer.com/content/pdf/10.1007/s11239-022-02668-8.pdf

publisherhttps://link.springer.com/article/10.1007/s11239-022-02668-8/fulltext.html

journalhttps://doi.org/10.1007/s11239-022-02668-8

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35689140

Fields of Study

Atrial Fibrillation Management and OutcomesVenous Thromboembolism Diagnosis and ManagementAcute Ischemic Stroke Management03 medical and health sciences0302 clinical medicine

MeSH Terms

RivaroxabanAdministration, OralAnticoagulantsAtrial FibrillationHemorrhageHumansObesity, MorbidRetrospective StudiesThinnessWarfarinStrokeVenous Thromboembolism

Keywords

MedicineWarfarinInternal medicineAtrial fibrillationApixabanDabigatranUnderweightBody mass indexEdoxabanRivaroxabanStroke (engine)Retrospective cohort studyOverweightBMIObeseDoacRecurrent ThromboembolismSevere BleedingExtreme Body WeightAdministration, OralAnticoagulantsHemorrhageVenous ThromboembolismObesity, MorbidStrokeThinnessHumansRetrospective Studies

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 3: 3. Good healthSDG 0: Good health and well-being